# Omnicell Inc. ($0.001 par value) (OMCL) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $35.46, market value $1.6 billion.

## Valuation
- **P/E (trailing): 36.9×** (5-yr avg 457.2×, 3-yr avg 648.7×). Omnicell Inc. ($0.001 par value) trades at 36.9× trailing earnings, well below its own five-year average of 457.2×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 17.7×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 1.3×**. Each dollar of revenue is priced at 1.3×.
- **Price / book: 1.2×**. The shares trade at 1.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 10.9×**. Enterprise value is 10.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 8.8%** (5-yr avg 4.7%). Free cash flow equals 8.8% of the market value, above its five-year average of 4.7%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 2.7%**. The inverse of the P/E: 2.7% of the price is earned each year.

## Profitability
- **Gross margin: 44.8%**. Omnicell Inc. ($0.001 par value) keeps 44.8% of revenue after the direct cost of what it sells.
- **Operating margin: 4.6%**. 4.6% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 0.2%**. 0.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 0.2%**. 0.2% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 4.2%**. Return on all capital, debt included, is 4.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 2.0%**. Each dollar of assets produces 2.0% of profit.

## Growth
- **Revenue growth (1 yr): 6.5%** (3-yr -2.9%/yr, 5-yr 5.8%/yr). Revenue grew 6.5% over the last year, against 5.8% a year compounded over five years.
- **EPS growth (1 yr): -85.2%** (3-yr -30.7%/yr, 5-yr -44.2%/yr). Earnings per share fell 85.2%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 42.2%/yr**. Free cash flow has compounded at 42.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.04**. Debt is 0.04 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Omnicell Inc. ($0.001 par value) holds more cash than debt.
- **Current ratio: 1.43** (quick 1.43). Current assets cover the next year's liabilities 1.43 times.
- **Altman Z-score: 2.91**. A Z-score of 2.91 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Omnicell Inc. ($0.001 par value) does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover Omnicell Inc. ($0.001 par value); the consensus is strong_buy, with an average price target of $57.71 (+63% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 8.5%** (YTD -19.6%, 3-mo -3.3%). The shares are up 8.5% over twelve months including dividends.
- **From 52-week high: -35.5%** (11.7% above the low). Trading 36% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 0.93** (volatility 49%). Beta of 0.93 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OMCL · Page: https://foliofundamentals.com/stocks/omcl

Not investment advice.